drugset / Trial / NCT02239380

Lorazepam for the Treatment of Status Epilepticus or Repetitive Status Epilepticus in Japan

NCT02239380

Phase 3 Completed 26 enrolled Pfizer
Parallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the efficacy, safety and pharmacokinetics of Lorazepam on Japanese patients with Status Epilepticus or Repetitive Status Eplilepticus.

Timeline

Start
2014-11
Primary completion
2016-08
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Lorazepam Small molecule 0.05 mg/kg Intravenous
Subject Lorazepam Small molecule 4 mg Intravenous

Indications

No indication recorded.